Retatrutide vs Lactoferricin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Lactoferricin
Lactoferricin is an antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. It has potent antibacterial, antiviral, and antifungal properties.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Lactoferricin |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Binds to and disrupts microbial membranes through electrostatic interactions. Also binds to lipopolysaccharide (LPS) to neutralize endotoxins and has immunomodulatory effects. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Research applications vary widely. Oral lactoferrin supplements (containing lactoferricin precursor) typically dosed at 100-400mg daily. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Available through lactoferrin supplementation orally. Purified lactoferricin primarily used in research settings. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Lactoferrin supplementation is generally well-tolerated. May cause GI upset in some individuals. Derived from milk so caution with dairy allergies. |
| Best For |